CONTEXT: Pain is a commonly experienced and distressing symptom in women with breast cancer (BCA), and recent evidence suggests that immune activation may be associated with pain and other co-occurring symptoms. However, no studies to date have explored the relationships among perceived pain and biomarkers of inflammation in women with early-stage BCA during the initial course of treatment. OBJECTIVES: The purpose of this research study was to examine the relationships among pro- and anti-inflammatory biomarkers and the presence of pain and other symptoms (anxiety, depression, fatigue, and sleep disorder) prior to induction of chemotherapy. METHOD: This was a secondary analysis of data that measured perceived symptoms, including the presence of pain and pain interference, and plasma levels of pro- and anti-inflammatory cytokines and C-reactive protein (CRP) in women with early-stage BCA (N = 32) at 1 month postsurgery but prior to induction of chemotherapy. RESULTS: Women experiencing pain had significantly higher levels of CRP (p < .01), interleukin (IL) 13 (p < .02), and IL-7 (p < .02) and more pain interference (p < .01), depression (p < .01), and sleep disturbance (p < .01) compared to women reporting no pain. CONCLUSION: The presence of pain during the initial course of treatment in women with early-stage BCA was associated with significantly higher levels of CRP, IL-7, and IL-13, suggesting a potential role of immune activation in perceived pain. Further research to examine the precise effects of these biological factors in modulating pain is needed. Perceived pain was also associated with multiple co-occurring symptoms, and this finding has important implications for symptom management.
CONTEXT: Pain is a commonly experienced and distressing symptom in women with breast cancer (BCA), and recent evidence suggests that immune activation may be associated with pain and other co-occurring symptoms. However, no studies to date have explored the relationships among perceived pain and biomarkers of inflammation in women with early-stage BCA during the initial course of treatment. OBJECTIVES: The purpose of this research study was to examine the relationships among pro- and anti-inflammatory biomarkers and the presence of pain and other symptoms (anxiety, depression, fatigue, and sleep disorder) prior to induction of chemotherapy. METHOD: This was a secondary analysis of data that measured perceived symptoms, including the presence of pain and pain interference, and plasma levels of pro- and anti-inflammatory cytokines and C-reactive protein (CRP) in women with early-stage BCA (N = 32) at 1 month postsurgery but prior to induction of chemotherapy. RESULTS:Women experiencing pain had significantly higher levels of CRP (p < .01), interleukin (IL) 13 (p < .02), and IL-7 (p < .02) and more pain interference (p < .01), depression (p < .01), and sleep disturbance (p < .01) compared to women reporting no pain. CONCLUSION: The presence of pain during the initial course of treatment in women with early-stage BCA was associated with significantly higher levels of CRP, IL-7, and IL-13, suggesting a potential role of immune activation in perceived pain. Further research to examine the precise effects of these biological factors in modulating pain is needed. Perceived pain was also associated with multiple co-occurring symptoms, and this finding has important implications for symptom management.
Authors: Christine Miaskowski; Bruce A Cooper; Steven M Paul; Marylin Dodd; Kathryn Lee; Bradley E Aouizerat; Claudia West; Maria Cho; Alice Bank Journal: Oncol Nurs Forum Date: 2006-09-01 Impact factor: 2.172
Authors: Orazio Caffo; Maurizio Amichetti; Antonella Ferro; Antonio Lucenti; Francesco Valduga; Enzo Galligioni Journal: Breast Cancer Res Treat Date: 2003-07 Impact factor: 4.872
Authors: Alicia Collado-Hidalgo; Julienne E Bower; Patricia A Ganz; Michael R Irwin; Steve W Cole Journal: Brain Behav Immun Date: 2008-07-09 Impact factor: 7.217
Authors: Kathleen T Hickey; Suzanne Bakken; Mary W Byrne; Donald Chip E Bailey; George Demiris; Sharron L Docherty; Susan G Dorsey; Barbara J Guthrie; Margaret M Heitkemper; Cynthia S Jacelon; Teresa J Kelechi; Shirley M Moore; Nancy S Redeker; Cynthia L Renn; Barbara Resnick; Angela Starkweather; Hilaire Thompson; Teresa M Ward; Donna Jo McCloskey; Joan K Austin; Patricia A Grady Journal: Nurs Outlook Date: 2019-01-18 Impact factor: 3.250
Authors: An De Groef; Nele Devoogdt; Ceren Gursen; Niamh Moloney; Victoria Warpy; Jolien Daelemans; Lore Dams; Vincent Haenen; Elien Van der Gucht; An-Kathleen Heroes; Tessa De Vrieze; Elizabeth Dylke Journal: J Cancer Surviv Date: 2021-08-28 Impact factor: 4.062
Authors: Marilyn Huckans; Bret Fuller; Viva Wheaton; Sarah Jaehnert; Carilyn Ellis; Michael Kolessar; Daniel Kriz; Jeanne Renee Anderson; Kristin Berggren; Hannah Olavarria; Anna W Sasaki; Michael Chang; Kenneth D Flora; Jennifer M Loftis Journal: J Psychosom Res Date: 2014-08-07 Impact factor: 3.006
Authors: Christina Van Onselen; Bradley E Aouizerat; Laura B Dunn; Steven M Paul; Claudia West; Deborah Hamolsky; Kathryn Lee; Michelle Melisko; John Neuhaus; Christine Miaskowski Journal: Breast Date: 2012-08-01 Impact factor: 4.380
Authors: Jennifer Fazzari; Jesse Sidhu; Shreya Motkur; Mark Inman; Norman Buckley; Mark Clemons; Lisa Vandermeer; Gurmit Singh Journal: J Pain Res Date: 2020-02-07 Impact factor: 3.133
Authors: K G Oliveira; S V von Zeidler; A Z Lamas; J R V de Podestá; A Sena; E D Souza; J Lenzi; E M Lemos; S A Gouvea; N S Bissoli Journal: Braz J Med Biol Res Date: 2014-05-30 Impact factor: 2.590